**Kiribati**  
Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms

1. **Country**: Kiribati
2. **Grant number(s)**: 19-KIR-25d-X/15-KIR-08h-Y
3. **Date of Decision Letter**: 8 March 2019. This replaces the previous decision letter for IPV dated 22 July 2017.
4. **Date of the Partnership Framework Agreement (PFA)**: 22 July 2014
5. **Programme title**: NVS, IPV routine
6. **Vaccine type**: Inactivated Polio Vaccine (IPV)
7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID
8. **Programme duration**: 2015 - 2019
9. **Indicative Programme Budget**: (subject to the terms of the PFA, if applicable)
   Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015-2018</th>
<th>2019</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme</td>
<td>35,727</td>
<td>12,500</td>
<td>48,227</td>
</tr>
<tr>
<td>Total Budget</td>
<td>35,727</td>
<td>12,500</td>
<td>48,227</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant**: US$ 100,000 paid on 21 August 2014

11. **Indicative Annual Amounts**: (subject to the terms of the PFA, if applicable)

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2015-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td>3,600</td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>35,727</td>
<td>12,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency**: UNICEF.

13. **Self-procurement**: Not applicable.

14. **Co-financing obligations**: Not applicable.

---

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the Programme.
3 This is the total amount endorsed by Gavi for 2015 to 2019.
4 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
5 This is the amount that Gavi has approved.
Gavi’s usual co-financing requirements do not apply to IPV. However, Kiribati is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for catch-up campaigns: Not applicable

16. Additional reporting requirements:

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td>
<td></td>
</tr>
<tr>
<td>• Vaccine stock levels including buffer stock, by end March;</td>
<td>31 March 2019</td>
</tr>
<tr>
<td>• Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</td>
<td>15 May 2019</td>
</tr>
<tr>
<td>Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td></td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. Financial clarifications: Not applicable

18. Other conditions:
Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Kiribati envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Kiribati.

Signed by,

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
8 March 2019